Cogstate (CGS) AGM 2025 summary

Opening remarks and agenda

• The meeting opened with a welcome, acknowledgment of traditional custodians, confirmation of quorum, and Board introductions.

• Chairman highlighted record performance, strategic progress, and future growth momentum.

• Shareholders could participate and ask questions both in-person and online, with clear instructions for engagement.

• Acknowledgement of the dedication and expertise of the entire organization.

• Announcement of the first ever Shareholder Day to be held in Melbourne.

Financial performance review

• FY25 revenue reached $53.1 million, up 22%, with clinical trials revenue at $50.6 million, up 28%.

• Profit before tax was $13.9 million, up 96%, and NPAT was $10.1 million, up 86%.

• EBITDA margin expanded to 30% and EBIT margin to 25%; gross margin reached 61%.

• Operating cash flow was $11.5 million; cash balance stood at $35.6 million after a $4.8 million share buyback.

• FY26 began strongly with $21.4 million in sales contracts in Q1.

Board and executive committee updates

• Board introduced, including new and reelected members, and acknowledgment of a retiring director's long service.

• CEO Brad O’Connor highlighted the executive team's strength and ongoing leadership.